Rymarz Zdort has advised Polski Bank Komorek Macierzystych on a voluntary public offering to exchange shares in PBKM for shares in Vita 34, following their business combination agreement in May 2021. DLA Piper advised Vita 34 on the deal.
According to Rymarz Zdort, “the transaction was the first cross-border exchange offer in Poland carried out by a German company for a Polish listed company, and one of a very few exchange offerings on the Polish market executed to date. With an acceptance rate of 98%, this exchange offer was one of the most successful transactions ever conducted on the Polish capital market.”
PBKM leads the international FamiCord Group and manages stem cell banks located in Europe. The FamiCord Group stores 610,000 samples belonging to over 450,000 families.
Vita 34, founded in 1997 in Leipzig, is a cell bank. As Europe's first private cord blood bank, the company has since offered collection logistics, processing, and the storage of stem cells from umbilical cord blood and tissue as a full-service provider for cryopreservation.
The Rymarz Zdort team was led by Partner Jacek Zawadzki and included Managing Partner Pawel Rymarz, Partner Monika Kierepa, Counsel Marek Kanczew, Senior Associate Michal Chyla, and Associates Aleksander Jakubisiak and Malgorzata Derus.
The DLA Piper team was led by Frankfurt-based Partners Andreas Fuchsel and Roland Maass and Warsaw-based Counsel Wojciech Kalinowski and included team members in Warsaw, Bucharest, Budapest, Frankfurt, Cologne, Madrid, Milan, Lisbon, and London.
